CD274 and non-small cell lung carcinoma: Here, we performed a joint analysis of CNVs and fragmentation features in cfDNA of 49 advanced NSCLC patients using samples before and after 4 cycles of anti-PD-(L)1 therapy to explore the potential clinical utility of these markers.